Subcommittee on Neurological Disease committee  We only have a few drugs that treat Alzheimer's that have been approved for use within Canada within the last six or seven years. We generally see this all across mental health drugs, including drugs for Alzheimer's. So we don't have, let's say, a basket of ten to look at. We're

Subcommittee on Neurological Disease committee  I'll provide you with a list of the drugs. Some of the lists are extensive. The challenge is that in Canada, across the country, we basically do not see a form of public coverage for those same drugs. What we tend to see is that the drugs will have been reviewed by the common dru

Subcommittee on Neurological Disease committee  It depends, because all sorts of factors influence investments.

Subcommittee on Neurological Disease committee  For instance, patent laws may have an influence. In the private sector if you want patent protection, a certain market exclusivity that rewards the investments that the private company makes in research, that can attract funds. For instance, the United States quite recently passe

Subcommittee on Neurological Disease committee  Yes. At least that is the case for vaccines against Alzheimer's disease. There have not been any successes in the past few years, in spite of the large amount of research that is being done in this field. Since the 1990s and the beginning of the last decade there has of course be

Subcommittee on Neurological Disease committee  Indeed, because in my opinion, we are just beginning to evaluate the research that is being done, in the universities in particular, here and elsewhere, on the prevention of certain mental illnesses. So as we are just in the preliminary stages of the development of vaccines which

Subcommittee on Neurological Disease committee  Thank you, Dr. Duncan. I'd be happy to table with the committee actual graphs and further information so that it's clearer, but I would just say that we were able to identify, based on our international report on access to medicines, 150 drugs, 33 of which were cancer drugs. Tha

Subcommittee on Neurological Disease committee  We'll do that. It will be clearer, I think, to see the information in that form.

Subcommittee on Neurological Disease committee  Thank you, Madam Chair. Good morning to everyone. My name is Mark Ferdinand. I am the vice-president of policy and research at Canada's Research-Based Pharmaceutical Companies, otherwise known as Rx & D. I have two modest goals to share with you today: first, to present

Subcommittee on Neurological Disease committee  Very well. Canada ranks 26th out of the 29 OECD countries for public health plan reimbursement of medicines. Canadians expect better and deserve better. The results of the Rx&D International Report on Access to Medication, the RIAM, put the emphasis on diseases that are of

Finance committee  I'm trying to understand the question.

Finance committee  We certainly will. As of tomorrow we'll be able to share that with the committee.

Finance committee  Right. I think under current rules there is a period that allows companies to carry forward unused amounts and also allows them to look back three years, I believe, if they haven't used that, so they can apply it both forward and backwards if necessary.

Finance committee  The current rules allow for both, and I think we'd want refundability--

Finance committee  Tomorrow we're going to be submitting our submission to the Department of Finance. We've tried to cost out a few of the options that we're looking for recommendations on. One of the issues that we'll have to consider is that when the finance department conducted its consultations